In isotope production, we are perfectly set up as a research reactor. We feed into the CANDU. One of the beautiful things about a CANDU reactor is that it is also multi-purpose, and we can produce medical isotopes at the same time as producing electricity without any impact.
The really beautiful role for the research reactors is that we don't want to put anything into a CANDU that hasn't been fully developed and fully explored. We want to be on the leading edge of that, all the way up to a phase one, phase two clinical trial, and then you would really pass that. You would be looking at going to a commercial production in which you might be, at that time, looking at something like a CANDU to produce isotopes.
As a limitation for us, we haven't outpaced that yet. We're still growing, but there will come a time when we'll be full. The radiopharmaceutical industry is growing rapidly. I think it's going to be $40 billion by 2032, or something like that. As it's growing really rapidly, we want to be thinking about next-generation medical isotopes. We want those new treatments to be coming to Canadians.
It's not just about isotope production. It's a whole suite of things. We need to do preclinical discovery research. We also need to be doing radiopharmaceutical production, which occurs in clean rooms. I mean, we can take it all the way up at McMaster to phase one, phase two, but we want to be able to accelerate that process so that it keeps the intellectual property within Canada and it brings new treatment options to Canadians. Usually, our sickest patients with advanced cancers are involved in these things.
